Tempus AI, Inc. (TEM)Healthcare | Health Information Services | Chicago, United States | NasdaqGS
55.93 USD
-2.30
(-3.950%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 55.30 -0.63 (-0.630%) ⇩ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:44 a.m. EDT
The immediate outlook is driven by aggressive speculative positioning rather than fundamental clarity. While the stock has rallied 52% year-to-date, the underlying business remains unprofitable with negative operating margins and a forward P/E that is mathematically undefined due to losses. This disconnect creates a high-risk environment where the price is decoupled from current earnings reality. The options market is screaming bullishness, with heavy call buying establishing significant resistance levels around $60-$70, yet this optimism is not backed by a turnaround in profitability or a fortress balance sheet. The recent insider selling by the CEO and other officers further dampens confidence in the near-term catalysts required to sustain this rally. Consequently, while the momentum is technically intact, the lack of fundamental support and the presence of key resistance levels suggest a volatile, high-beta trade rather than a stable investment opportunity. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.070483 |
| MSTL | 0.071631 |
| AutoARIMA | 0.071712 |
| AutoTheta | 0.073219 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.273 |
| Excess Kurtosis | -0.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 316.647 |
| Revenue per Share | 7.735 |
| Market Cap | 10,043,057,152 |
| Forward P/E | -536.91 |
| Beta | 3.46 |
| Profit Margins | -22.20% |
| Previous Name | Tempus AI, Inc |
| Website | https://www.tempus.com |
As of July 11, 2026, 3:44 a.m. EDT: Speculators are aggressively positioning for upside, evidenced by massive open interest walls at strikes like $60, $65, and $70 across multiple expirations. Call volume significantly exceeds put volume, particularly in the out-of-the-money range, while implied volatility remains elevated relative to historical norms, suggesting a consensus expectation of continued volatility and potential price appreciation despite the lack of insider buying.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.007090926 |
| Address1 | 600 West Chicago Avenue |
| Address2 | Suite 510 |
| All Time High | 104.32 |
| All Time Low | 22.89 |
| Ask | 58.86 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 6,018,620 |
| Average Daily Volume3 Month | 6,617,509 |
| Average Volume | 6,617,509 |
| Average Volume10Days | 6,018,620 |
| Beta | 3.462 |
| Bid | 52.56 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.323 |
| City | Chicago |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 55.93 |
| Current Ratio | 3.315 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 57.95 |
| Day Low | 55.11 |
| Debt To Equity | 316.647 |
| Display Name | Tempus AI |
| Earnings Call Timestamp End | 1,785,441,600 |
| Earnings Call Timestamp Start | 1,785,441,600 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,785,441,600 |
| Earnings Timestamp Start | 1,785,441,600 |
| Ebitda | -185,246,000 |
| Ebitda Margins | -0.13579 |
| Enterprise To Ebitda | -57.883 |
| Enterprise To Revenue | 7.86 |
| Enterprise Value | 10,722,516,992 |
| Eps Current Year | -0.38083 |
| Eps Forward | -0.10417 |
| Eps Trailing Twelve Months | -1.72 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 800 893 0276 |
| Fifty Day Average | 51.3592 |
| Fifty Day Average Change | 4.570801 |
| Fifty Day Average Change Percent | 0.08899673 |
| Fifty Two Week Change Percent | 0.7090926 |
| Fifty Two Week High | 104.32 |
| Fifty Two Week High Change | -48.39 |
| Fifty Two Week High Change Percent | -0.4638612 |
| Fifty Two Week Low | 41.73 |
| Fifty Two Week Low Change | 14.200001 |
| Fifty Two Week Low Change Percent | 0.3402828 |
| Fifty Two Week Range | 41.73 - 104.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,718,371,800,000 |
| Float Shares | 114,273,222 |
| Forward Eps | -0.10417 |
| Forward P E | -536.9108 |
| Free Cashflow | -55,760,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 3,800 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.63389 |
| Gross Profits | 864,734,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37124002 |
| Held Percent Institutions | 0.5703 |
| Implied Shares Outstanding | 179,564,767 |
| Industry | Health Information Services |
| Industry Disp | Health Information Services |
| Industry Key | health-information-services |
| Ipo Expected Date | 2,024-06-14 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois. |
| Long Name | Tempus AI, Inc. |
| Market | us_market |
| Market Cap | 10,043,057,152 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_421843712 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -302,910,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,456,056,381 |
| Number Of Analyst Opinions | 16 |
| Open | 57.63 |
| Operating Cashflow | -185,743,008 |
| Operating Margins | -0.24334998 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 800 976 5448 |
| Post Market Change | -0.63000107 |
| Post Market Change Percent | -1.1264099 |
| Post Market Price | 55.3 |
| Post Market Time | 1,783,987,188 |
| Prev Name | Tempus AI, Inc |
| Previous Close | 58.23 |
| Price Eps Current Year | -146.86343 |
| Price Hint | 2 |
| Price To Book | 24.076626 |
| Price To Sales Trailing12 Months | 7.3620386 |
| Profit Margins | -0.22205 |
| Quick Ratio | 2.993 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.11111 |
| Region | US |
| Regular Market Change | -2.3 |
| Regular Market Change Percent | -3.94985 |
| Regular Market Day High | 57.95 |
| Regular Market Day Low | 55.11 |
| Regular Market Day Range | 55.11 - 57.95 |
| Regular Market Open | 57.63 |
| Regular Market Previous Close | 58.23 |
| Regular Market Price | 55.93 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 4,110,278 |
| Return On Assets | -0.090679996 |
| Return On Equity | -0.81581 |
| Revenue Growth | 0.361 |
| Revenue Per Share | 7.735 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 174,520,978 |
| Shares Percent Shares Out | 0.1871 |
| Shares Short | 33,602,707 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 31,128,255 |
| Short Name | Tempus AI, Inc. |
| Short Percent Of Float | 0.3394 |
| Short Ratio | 4.52 |
| Source Interval | 15 |
| State | IL |
| Symbol | TEM |
| Target High Price | 100.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 66.0625 |
| Target Median Price | 64.0 |
| Total Cash | 639,072,000 |
| Total Cash Per Share | 3.559 |
| Total Debt | 1,318,531,968 |
| Total Revenue | 1,364,167,936 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.72 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 62.398773 |
| Two Hundred Day Average Change | -6.468773 |
| Two Hundred Day Average Change Percent | -0.10366827 |
| Type Disp | Equity |
| Volume | 4,110,278 |
| Website | https://www.tempus.com |
| Zip | 60,654 |